Predictors of Treatment with Duloxetine or Venlafaxine XR among Adult Patients Treated for Depression in Primary Care Practices in the United Kingdom

Table 2

Pre-period clinical characteristics of patients initiating duloxetine or venlafaxine XR.

	Duloxetine		Venlafaxine XR		𝑃 value
	𝑛	%	𝑛	%
Diagnosed pain conditions^1
Diabetic peripheral neuropathy	3	0.3%	2	0.2%	0.398
Fibromyalgia	48	5.3%	46	3.6%	0.052
Osteoarthritis	62	6.8%	74	5.8%	0.307
Chronic low-back pain	14	1.5%	4	0.3%	0.002
Unexplained pain	413	45.4%	431	33.5%	<0.001
Diagnosed psychiatric conditions^1
Anxiety disorders	190	20.9%	315	24.5%	0.049
Attention deficit hyperactivity disorder	0	0.0%	2	0.2%	0.234
Schizophrenia	2	0.2%	6	0.5%	0.345
Bipolar disorder	8	0.9%	10	0.8%	0.793
Alcohol/drug dependence	43	4.7%	69	5.4%	0.505
Other diagnosed conditions^1
Diseases of the circulatory system	207	22.8%	204	15.9%	<0.001
Diseases of the respiratory system	470	51.7%	571	44.4%	<0.001
Diseases of the digestive system	317	34.9%	378	29.4%	0.007
Sleep disorders	95	10.5%	133	10.3%	0.934
Diabetes	60	6.6%	36	2.8%	<0.001
Healthcare utilization^2
Inpatient admission	188	20.7%	224	17.4%	0.054
Accident and emergency Visits	207	22.8%	245	19.1%	0.034

¹Comorbid conditions were evaluated during 36-month pre-index period.
²Healthcare utilization was evaluated during 12-month pre-index period.